{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:44:40Z","timestamp":1762249480215},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T00:00:00Z","timestamp":1381104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0076482","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T21:00:51Z","timestamp":1381179651000},"page":"e76482","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures"],"prefix":"10.1371","volume":"8","author":[{"given":"Isabella","family":"Bon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rusnati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cl\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Morini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Grigolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo","family":"Landolfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carla","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Gibellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","article-title":"HIV epidemiology and the effects of antiviral therapy on long-term consequences","volume":"22","author":"TC Quinn","year":"2009","journal-title":"AIDS"},{"key":"ref2","unstructured":"WHO (2011) Global HIV\/AIDS Response: Epidemic update and health sector progress towards Universal Access Progress report 2011. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/data\/en\/Accessed\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/data\/en\/Accessed<\/ext-link> 2013 May10."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"a007435","DOI":"10.1101\/cshperspect.a007435","article-title":"Behavioral and biomedical combination strategies for HIV prevention","volume":"2","author":"LG Bekker","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"S Broder","year":"2010","journal-title":"Antiviral Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkn455","article-title":"Eradication of HIV: current challenges and new directions","volume":"63","author":"MD Marsden","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0b013e32834134ea","article-title":"Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.","volume":"6","author":"F Maldarelli","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1086\/595701","article-title":"HIV\/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations","volume":"48","author":"LE Wilson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.antiviral.2009.09.016","article-title":"HIV reservoirs, latency, and reactivation: prospects for eradication","volume":"85","author":"V Dahl","year":"2012","journal-title":"Antivir Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nri1848","article-title":"Microbicides and other topical strategies to prevent vaginal transmission of HIV","volume":"6","author":"MM Lederman","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(08)60886-7","article-title":"Behavioural strategies to reduce HIV transmission: How to make them work better","volume":"372","author":"T Coates","year":"2008","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0b013e32834ddc96","article-title":"HIV vaccine development at the turn of the 21st century","volume":"7","author":"MP Girard","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1016\/j.vaccine.2011.06.085","article-title":"Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review.","volume":"29","author":"MP Girard","year":"2011","journal-title":"Vaccine"},{"key":"ref13","first-page":"104","article-title":"HIV and sexually transmitted diseases: lethal synergy","volume":"12","author":"MS Cohen","year":"2004","journal-title":"Top HIV Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2105\/AJPH.2009.159723","article-title":"Rethinking gender, heterosexual men, and women&apos;s vulnerability to HIV\/AIDS","volume":"100","author":"JA Higgins","year":"2010","journal-title":"Am J Public Health"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1742-4690-5-116","article-title":"Topical application of entry inhibitors as &quot;virustats&quot; to prevent sexual transmission of HIV infection","volume":"5","author":"MM Lederman","year":"2008","journal-title":"Retrovirology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.med.59.061206.112737","article-title":"Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission","volume":"59","author":"PJ Klasse","year":"2008","journal-title":"Annu Rev Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.pharmtox.48.113006.094847","article-title":"Targeting chemokine receptors in HIV: a status report","volume":"48","author":"SE Kuhmann","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.aids.0000161771.44276.92","article-title":"Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers","volume":"19","author":"RJ Smith","year":"2005","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/sti.2008.032458","article-title":"How much could a microbicide&apos;s sexually transmitted infection efficacy contribute to reducing HIV risk and the level of condom use needed to lower risk? Model estimates","volume":"85","author":"AM Foss","year":"2009","journal-title":"Sex Transm Infect"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","volume":"10","author":"E De Clerq","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QCO.0b013e328334fe70","article-title":"Microbicides for HIV prevention: reality or hope?","volume":"23","author":"I McGowan","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QCO.0b013e328334de6d","article-title":"Microbicides and HIV prevention: lessons from the past, looking to the future","volume":"23","author":"GC Morris","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"ref23","first-page":"1168","article-title":"CAPRISA 004 Trial Group","volume":"329","author":"Q Abdool Karim","year":"2010","journal-title":"Science"},{"key":"ref24","first-page":"21","article-title":"Oral tenofovir arm of VOICE trial discontinued early","volume":"15","author":"R McEnery","year":"2011","journal-title":"IAVI Rep"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/QAD.0b013e328355ce08","article-title":"Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial","volume":"26","author":"A Grobler","year":"2012","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0b013e3283522272","article-title":"Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention","volume":"26","author":"A Van der Straten","year":"2012","journal-title":"AIDS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1367-5931(02)00400-3","article-title":"Biological applications of dendrimers","volume":"6","author":"MJ Cloninger","year":"2002","journal-title":"Curr Opin Chem Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/mp050023q","article-title":"Dendrimers as drugs, discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention.","volume":"2","author":"TD McCarthy","year":"2005","journal-title":"Mol. Pharm"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1568005054880127","article-title":"Dendrimers and antivirals, a review","volume":"5","author":"A Rosa Borges","year":"2005","journal-title":"Curr Drug Targets Infect Disord"},{"key":"ref33","first-page":"331","article-title":"Dendrimer based anti-infective and antiinflammatory drugs","volume":"1","author":"PM Heegaard","year":"2006","journal-title":"Rec Pat Anti-Infect Drug Discov"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/AAC.48.10.3834-3844.2004","article-title":"In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission","volume":"48","author":"CS Dezzutti","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1086\/462424","article-title":"A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection","volume":"192","author":"SR Abner","year":"2005","journal-title":"J Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.03.186","article-title":"Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1","volume":"90","author":"S Telwatte","year":"2011","journal-title":"Antiviral Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2005.21.207","article-title":"SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques","volume":"21","author":"YH Jiang","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1128\/AAC.49.7.2665-2672.2005","article-title":"Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification","volume":"49","author":"A Pini","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.antiviral.2010.01.003","article-title":"Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate","volume":"85","author":"A Luganini","year":"2010","journal-title":"Antiviral Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.00471-10","article-title":"Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses","volume":"54","author":"M Donalisio","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1128\/AAC.00771-12","article-title":"Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide","volume":"56","author":"M Donalisio","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Gartner S, Popovic M (1990) Virus Isolation and production. In AldoviniA, WalkerBD. Editors.HIV techniques, Stockton Press NY pp 53\u201369.","DOI":"10.1007\/978-1-349-11888-5_3"},{"key":"ref43","first-page":"195","article-title":"Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay, results from the OSCAR Study Group","volume":"33","author":"V Svicher","year":"2010","journal-title":"New Microbiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1074\/jbc.M006701200","article-title":"Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans","volume":"276","author":"M Tyagi","year":"2001","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jviromet.2003.09.030","article-title":"Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients","volume":"115","author":"D Gibellini","year":"2004","journal-title":"J Virol Meth"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1386-6532(03)00169-0","article-title":"Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique","volume":"29","author":"D Gibellini","year":"2004","journal-title":"J Clin Virol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JVI.72.5.3623-3634.1998","article-title":"Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans","volume":"72","author":"I Mondor","year":"1998","journal-title":"J Virol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/JVI.74.4.1948-1960.2000","article-title":"Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120","volume":"74","author":"M Moulard","year":"2000","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2009.07.022","article-title":"Entry inhibitors in the treatment of HIV-1 infection","volume":"85","author":"JC Tilton","year":"2010","journal-title":"Antivir Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.1128\/JVI.67.12.7383-7393.1993","article-title":"Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding","volume":"67","author":"QJ Sattentau","year":"1993","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1128\/JVI.69.9.5723-5733.1995","article-title":"Involvement of the V1\/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding","volume":"69","author":"R Wyatt","year":"1995","journal-title":"J Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"PD Kwong","year":"1998","journal-title":"Nature"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1126\/science.280.5371.1949","article-title":"A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding","volume":"280","author":"CD Rizzuto","year":"1998","journal-title":"Science"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1128\/JVI.76.21.10791-10800.2002","article-title":"Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding","volume":"76","author":"S Basmaciogullari","year":"2002","journal-title":"J Virol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"W Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/138161207779313722","article-title":"HIV entry inhibitors targeting gp41, from polypeptides to small-molecule compounds","volume":"13","author":"S Liu","year":"2007","journal-title":"Curr Pharm Des"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.antiviral.2006.12.006","article-title":"Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1","volume":"74","author":"DK Chang","year":"2007","journal-title":"Antivir Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"40841","DOI":"10.1074\/jbc.R112.406272","article-title":"HIV entry and envelope glycoprotein-mediated fusion","volume":"287","author":"R Blumenthal","year":"2012","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"JM Kilby","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"JP Lalezari","year":"2003","journal-title":"AIDS"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-medated cell\u2013cell fusion","volume":"9","author":"C Wild","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2008.04.013","article-title":"Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro","volume":"377","author":"W Pang","year":"2008","journal-title":"Virology"},{"key":"ref63","first-page":"1813","article-title":"Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. Chem Med Chem","volume":"5","author":"L Cai","year":"2010"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.4049\/jimmunol.176.11.6900","article-title":"HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41","volume":"176","author":"AL Cole","year":"2006","journal-title":"J Immunol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2567.2006.02553.x","article-title":"The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct","volume":"121","author":"AL Cole","year":"2007","journal-title":"Immunology"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00002030-198910000-00003","article-title":"Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins","volume":"3","author":"JE Hansen","year":"1989","journal-title":"AIDS"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.35.3.410","article-title":"Alpha-(1\u20133)- and alpha-(1\u20136)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob","volume":"35","author":"J Balzarini","year":"1991","journal-title":"Agents Chemother"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1126\/science.1083182","article-title":"Antibody domain exchange is an immunological solution tocarbohydrate cluster recognition","volume":"300","author":"DA Calarese","year":"2003","journal-title":"Science"},{"key":"ref69","first-page":"535","article-title":"Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses","volume":"19","author":"CC Tsai","year":"2003"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"T Mori","year":"2005","journal-title":"J Biol Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2009.07.013","article-title":"The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.","volume":"84","author":"D Huskens","year":"2009","journal-title":"Antiviral Res"},{"key":"ref72","first-page":"521770","article-title":"Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture","volume":"5","author":"JE Cummins Jr","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01328-07","article-title":"Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides","volume":"52","author":"C Lackman-Smith","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"e12309","DOI":"10.1371\/journal.pone.0012309","article-title":"Structure activity relationship of dendrimer microbicides with dual action antiviral activity","volume":"5","author":"SA Tyssen D. Henderson","year":"2010","journal-title":"PLoS ONE"},{"key":"ref75","volume":"55","unstructured":"Asaftei S, Huskens D, Schols D (2012) HIV-1 X4 activities of polycationic \u201cViologen\u201d based dendrimers by interaction with the chemokine receptor CXCR4, study of structure-activity relationship. J. Med. Chem. <volume>55<\/volume>: , 10405\u201310413"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/JVI.01366-08","article-title":"The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection","volume":"83","author":"NR Roan","year":"2009","journal-title":"J Virol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/JVI.01621-12","article-title":"Filoviruses utilize glycosaminoglycans for their attachment to target cells","volume":"87","author":"B Salvador","year":"2013","journal-title":"J Virol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"S Sarrazin","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0300-9084(01)01290-1","article-title":"Heparan sulfate, anchor for viral intruders?","volume":"83","author":"D Spillmann","year":"2001","journal-title":"Biochimie"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1083\/jcb.116.5.1273","article-title":"Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans","volume":"116","author":"MT Shieh","year":"1992","journal-title":"J Cell Biol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1128\/JVI.75.3.1565-1570.2001","article-title":"Human papillomavirus infection requires cell surface heparan sulfate","volume":"75","author":"T Giroglou","year":"2001","journal-title":"J Virol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1128\/JVI.74.14.6442-6447.2000","article-title":"The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate","volume":"74","author":"SA Feldman","year":"2000","journal-title":"J Virol"},{"key":"ref83","first-page":"41003","article-title":"Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate","volume":"278","author":"H Barth","year":"2003","journal-title":"J Biol Chem 2003"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm0897-866","article-title":"Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate","volume":"3","author":"Y Chen","year":"1997","journal-title":"Nat Med"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"12692","DOI":"10.1128\/JVI.79.20.12692-12702.2005","article-title":"Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells","volume":"79","author":"KS Jones","year":"2005","journal-title":"J Virol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/aid.1993.9.167","article-title":"Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines","volume":"9","author":"M Patel","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0966-842X(99)01474-2","article-title":"HIV-1 attachment, another look","volume":"7","author":"S Ugolini","year":"1997","journal-title":"Trends Microbiol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.1074\/jbc.M500911200","article-title":"Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site","volume":"280","author":"RR Viv\u00e8s","year":"2005","journal-title":"J Biol Chem"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/JVI.69.4.2233-2239.1995","article-title":"Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41","volume":"69","author":"G Roderiquez","year":"1995","journal-title":"J Virol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1348-0421.1996.tb01148.x","article-title":"Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection","volume":"40","author":"T Ohshiro Y. Murakami","year":"1996","journal-title":"Microbiol Immunol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JVI.72.5.3623-3634.1998","article-title":"Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans","volume":"72","author":"I Mondor","year":"1998","journal-title":"J Virol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.1128\/JVI.75.19.9187-9200.2001","article-title":"Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages","volume":"75","author":"ACS Saphire","year":"2001","journal-title":"J Virol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"12140","DOI":"10.1128\/JVI.77.22.12140-12151.2003","article-title":"Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts","volume":"77","author":"EG Argyris","year":"2003","journal-title":"J Virol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/emboj\/20.1.19","article-title":"The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface","volume":"20","author":"J Cladera","year":"2001","journal-title":"EMBO J"},{"key":"ref95","first-page":"600","article-title":"Next-generation oral preexposure prophylaxis, beyond tenofovir Curr Opin HIV AIDS","volume":"7","author":"BK Abraham","year":"2012"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0076482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T12:34:23Z","timestamp":1596630863000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0076482"}},"subtitle":[],"editor":[{"given":"William A.","family":"Paxton","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,7]]},"references-count":96,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0076482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,7]]}}}